Male Vs Female Comparison of High Rosuvastatin and Atorvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of Myocardial Periprocedural Necrosis. The ROMA II Gender Differences Sub-Study
暂无分享,去创建一个
M. Mancone | G. Sardella | S. Calcagno | S. Cimino | M. Pennacchi | R. Stio | L. Lucisano | E. Cavallo
[1] R. Kornowski,et al. Impact of female sex on long-term acute coronary syndrome outcomes , 2015, Coronary artery disease.
[2] Y. Jo,et al. Sterol-induced dislocation of 3-hydroxy-3-methylglutaryl coenzyme A reductase from membranes of permeabilized cells , 2013, Molecular biology of the cell.
[3] F. Fedele,et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. , 2013, International journal of cardiology.
[4] F. Fedele,et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: The ROMA trial , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] Maarten L. Simoons,et al. The third universal definition of myocardial infarction , 2013 .
[6] Li Jiang. Myocardial Infarction due to Percutaneous Coronary Intervention , 2011 .
[7] P. Barter,et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). , 2010, The American journal of cardiology.
[8] M. Roe,et al. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). , 2009, American heart journal.
[9] V. Pasceri,et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. , 2007, Journal of the American College of Cardiology.
[10] V. Vaccarino,et al. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions. , 2006, The American journal of cardiology.
[11] H. Tillmanns,et al. Gender Differences in the Outcome of Cardiac Interventions , 2005, Herz Kardiovaskuläre Erkrankungen.
[12] S. Behar,et al. Sex, age, and clinical presentation of acute coronary syndromes. , 2004, European heart journal.
[13] P. Presbitero,et al. Gender differences in the outcome of interventional cardiac procedures. , 2003, Italian heart journal : official journal of the Italian Federation of Cardiology.
[14] Elinor Miller,et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.
[15] A. Sposito,et al. Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[16] E. Topol,et al. Frequency and long-term impact of myonecrosis after coronary stenting. , 2002, European heart journal.
[17] J. Liao,et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[18] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[19] S. Reis,et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. , 1994, Circulation.
[20] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.